ClinicalTrials.Veeva

Menu
C

Centro de Investigacion Clinica de Oaxaca | Oaxaca, Mexico

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
MK-6482
TL-895
Durvalumab
Bevacizumab
LY2835219
Abiraterone
Abemaciclib
KRT-232
Atezolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 10 total trials

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse....

Active, not recruiting
Cytochrome P-450
Antineoplastic Agents, Hormonal
Drug: Placebo for Abemaciclib
Drug: Abiraterone

The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to...

Active, not recruiting
Carcinoma, Renal Cell
Drug: Belzutifan
Biological: Pembrolizumab

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the...

Active, not recruiting
Neoplasms
Drug: Cetuximab
Drug: Oxaliplatin

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenv...

Active, not recruiting
Carcinoma, Renal Cell
Drug: Belzutifan
Biological: Pembrolizumab/Quavonlimab

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Active, not recruiting
Advanced Breast Cancer
Drug: ARV-471
Drug: Fulvestrant

The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab,...

Active, not recruiting
Carcinoma, Ovarian Epithelial
Fallopian Tube Neoplasms
Drug: Bevacizumab
Biological: Pembrolizumab

This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy fo...

Active, not recruiting
Small Cell Lung Carcinoma
Drug: Cisplatin
Biological: Atezolizumab

This study evaluates either KRT-232 or TL-895 in treatment naïve patients with myelofibrosis (MF)The study will be conducted in 2 stages. Stage 1 wil...

Enrolling
Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)
Drug: TL-895
Drug: KRT-232

The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's...

Active, not recruiting
Breast Neoplasms
Drug: dextrose
Drug: liposomal doxorubicin

Researchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: carboplatin
Radiation: thoracic radiotherapy

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Lilly logo
Pfizer logo
Kartos Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems